These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31661699)

  • 1. Pneumocephalus in a Pediatric Patient with Glioma Receiving Trametinib.
    Gorsi H; Marupudi NI; Sood S; Altinok D; Yankelevich M
    Pediatr Neurosurg; 2020; 55(1):51-53. PubMed ID: 31661699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
    Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
    J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
    Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
    BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recalcitrant trametinib-induced paronychia treated successfully with topical timolol in a pediatric patient.
    Martínez-de-Espronceda I; Bernabeu-Wittel J; Azcona M; Monserrat MT
    Dermatol Ther; 2020 Jan; 33(1):e13164. PubMed ID: 31705590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series.
    Peterson RK; McKeown T; Tabori U; Bartels U; Bouffet E; Janzen L
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28690. PubMed ID: 32930446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trametinib for progressive pediatric low-grade gliomas.
    Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
    J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
    Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
    J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
    Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case.
    Giraud V; Longvert C; Houlle-Crepin S; Danel C; Labrune S; Camus P; Saiag P; Chinet T
    BMC Cancer; 2015 Oct; 15():732. PubMed ID: 26481107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.
    Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023
    [No Abstract]   [Full Text] [Related]  

  • 14. Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus: Related Findings?
    Egan G; Hamilton J; McKeown T; Bouffet E; Tabori U; Dirks P; Bartels U
    J Pediatr Hematol Oncol; 2020 May; 42(4):e248-e250. PubMed ID: 30676433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
    Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK
    Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
    J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.
    Boull C; Hook K; Moertel C; Maguiness S
    Pediatr Dermatol; 2017 Jan; 34(1):90-94. PubMed ID: 27981612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.
    Escuin-Ordinas H; Li S; Xie MW; Sun L; Hugo W; Huang RR; Jiao J; de-Faria FM; Realegeno S; Krystofinski P; Azhdam A; Komenan SM; Atefi M; Comin-Anduix B; Pellegrini M; Cochran AJ; Modlin RL; Herschman HR; Lo RS; McBride WH; Segura T; Ribas A
    Nat Commun; 2016 Aug; 7():12348. PubMed ID: 27476449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.